Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03735121 · OUTCOME

Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Source last updated 2025-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of HCPs
Interval / dispersion
Not reported
Time frame
After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)

What was measured

The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, how satisfied were you with atezolizumab SC? The responses to this question could be: Very satisfied; Satisfied; Dissatisfied; Very dissatisfied. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.

Analysis population: Overall number analyzed included HCPs who completed Question 4 of the questionnaire.

Groups in this outcome

Part 2: Atezolizumab SC 1875 mg

Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 2: Atezolizumab SC 1875 mg84

Reported measurements

Very satisfied
Values in percentage of HCPs · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 2: Atezolizumab SC 1875 mg34.5Not reportedNot reportedNot reportedNot reported
Satisfied
Values in percentage of HCPs · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 2: Atezolizumab SC 1875 mg50.0Not reportedNot reportedNot reportedNot reported
Dissatisfied
Values in percentage of HCPs · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 2: Atezolizumab SC 1875 mg13.1Not reportedNot reportedNot reportedNot reported
Very dissatisfied
Values in percentage of HCPs · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 2: Atezolizumab SC 1875 mg2.4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        34.5
    title
    Very satisfied
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        50.0
    title
    Satisfied
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        13.1
    title
    Dissatisfied
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        2.4
    title
    Very dissatisfied
denoms
  1. counts
    1. group Id
      OG000
      value
      84
    units
    Participants
description
The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, how satisfied were you with atezolizumab SC? The responses to this question could be: Very satisfied; Satisfied; Dissatisfied; Very dissatisfied. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.
groups
  1. description
    Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire.
    id
    OG000
    title
    Part 2: Atezolizumab SC 1875 mg
param Type
NUMBER
population Description
Overall number analyzed included HCPs who completed Question 4 of the questionnaire.
reporting Status
POSTED
time Frame
After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)
title
Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire
type
SECONDARY
unit Of Measure
percentage of HCPs

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice